Cureline, Inc.

Cureline, Inc. is a US-based Contract Research Organization (CRO) specializing in human biospecimen biobanking and laboratory services for translational and precision medicine. Founded in 2003 and headquartered in South San Francisco, US, Cureline, Inc. offers specialized services in human biospecimen biobanking and laboratory analysis.

The company has engaged in one deal, with its most recent deal occurring on January 6, 2026. The company was founded to serve pharmaceutical and biotechnology sectors, addressing the increasing demand for high-quality biobank resources. Cureline, Inc. is a prominent global Contract Research Organization (CRO) specializing in human biospecimen (HBS) biobanking and laboratory services tailored for translational and precision medicine.

The company offers a comprehensive suite of products and services including a global preclinical research human biobank, a translational histopathology laboratory, and a range of analytical services such as glycoproteomics and biomarker discovery and validation. Their offerings assist clients in accelerating drug research and development (R&D) as well as diagnostics development, targeting the pharmaceutical and biotechnology sectors. Cureline serves over 700 clients, partnering with 150+ validated clinical sites across Europe, Asia, Africa, and the Americas, providing essential products like preserved biofluids, fresh tissues, and FFPE tumor blocks for researchers and companies. Cureline’s revenue generation model is rooted in B2B transactions, primarily serving pharmaceutical and biotechnology firms through tailored partnerships and contracts.

Clients typically engage with Cureline for specific projects involving access to validated human biospecimens or laboratory services related to their R&D activities. The transaction structure often includes service agreements for biobanked samples, analytical services, and HBS validation studies, allowing clients to leverage Cureline's extensive resources in their research. Pricing plans are based on the specific services requested, reflecting the unique requirements of each project, though detailed pricing information is not publicly disclosed. Cureline's biobanking solutions and histopathology services form the backbone of its revenue stream, supporting its collaboration with scientific consortia and fostering growth in the precision medicine market.

In January 2026, Analytical Biological Services Inc. , a portfolio company of 3 Boomerang Capital, acquired Cureline, Inc. The rationale for this acquisition is to enable Analytical Biological Services Inc. to expand biospecimen access and streamline end-to-end execution.

The future growth strategy will likely focus on enhancing biospecimen access and operational efficiencies, although specific upcoming product launches and geographic expansions have not been detailed.